These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 34592006)

  • 21. The therapeutic efficacy of quercetin in combination with antiviral drugs in hospitalized COVID-19 patients: A randomized controlled trial.
    Shohan M; Nashibi R; Mahmoudian-Sani MR; Abolnezhadian F; Ghafourian M; Alavi SM; Sharhani A; Khodadadi A
    Eur J Pharmacol; 2022 Jan; 914():174615. PubMed ID: 34863994
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of favipiravir plus interferon-beta versus lopinavir/ritonavir plus interferon-beta in moderately ill patients with COVID-19: A randomized clinical trial.
    Hassaniazad M; Farshidi H; Gharibzadeh A; Bazram A; Khalili E; Noormandi A; Fathalipour M
    J Med Virol; 2022 Jul; 94(7):3184-3191. PubMed ID: 35292989
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Favipiravir for treating patients with novel coronavirus (COVID-19): protocol for a systematic review and meta-analysis of randomised clinical trials.
    Arab-Zozani M; Hassanipour S; Ghoddoosi-Nejad D
    BMJ Open; 2020 Jul; 10(7):e039730. PubMed ID: 32737100
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Favipiravir-induced Fever in a Patient with COVID-19.
    Kurita T; Ishida K; Muranaka E; Sasazawa H; Mito H; Yano Y; Hase R
    Intern Med; 2020; 59(22):2951-2953. PubMed ID: 33191372
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clindamycin-induced Maculopapular Exanthema with Preferential Involvement of Striae Distensae: A Koebner phenomenon?
    Monteagudo B; Cabanillas M; Iriarte P; Ramírez-Santos A; León-Muinos E; González-Vilas D; Suárez-Amor Ó
    Acta Dermatovenerol Croat; 2018 Apr; 26(1):61-63. PubMed ID: 29782303
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A review on favipiravir: the properties, function, and usefulness to treat COVID-19.
    Hashemian SM; Farhadi T; Velayati AA
    Expert Rev Anti Infect Ther; 2021 Aug; 19(8):1029-1037. PubMed ID: 33372567
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia.
    Khamis F; Al Naabi H; Al Lawati A; Ambusaidi Z; Al Sharji M; Al Barwani U; Pandak N; Al Balushi Z; Al Bahrani M; Al Salmi I; Al-Zakwani I
    Int J Infect Dis; 2021 Jan; 102():538-543. PubMed ID: 33181328
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Cutaneous adverse events of telaprevir/peginterferon/ribavirin therapy for chronic hepatitis C: A multicenter prospective cohort study].
    Lorcy S; Gaudy-Marqueste C; Botta D; Portal I; Quiles N; Oulies V; Mancini J; Grob JJ; Richard MA
    Ann Dermatol Venereol; 2016 May; 143(5):336-46. PubMed ID: 27161648
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adverse drug reactions and organ damage: The skin.
    Marzano AV; Borghi A; Cugno M
    Eur J Intern Med; 2016 Mar; 28():17-24. PubMed ID: 26674736
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emerging treatments in COVID-19: Adverse drug reactions including drug hypersensitivities.
    Manjaly Thomas ZR; Leuppi-Taegtmeyer A; Jamiolkowski D; Steveling-Klein E; Bellutti-Enders F; Scherer Hofmeier K; Hartmann K
    J Allergy Clin Immunol; 2020 Oct; 146(4):786-789. PubMed ID: 32710973
    [No Abstract]   [Full Text] [Related]  

  • 31. Role of favipiravir in the treatment of COVID-19.
    Joshi S; Parkar J; Ansari A; Vora A; Talwar D; Tiwaskar M; Patil S; Barkate H
    Int J Infect Dis; 2021 Jan; 102():501-508. PubMed ID: 33130203
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Favipiravir for the treatment of COVID-19 in elderly patients-what do we know after 2 years of COVID-19?
    Papp H; Lanszki Z; Keserű GM; Jakab F
    Geroscience; 2022 Jun; 44(3):1263-1268. PubMed ID: 35543795
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cutaneous reactions to proton pump inhibitors: a case-control study.
    Chularojanamontri L; Jiamton S; Manapajon A; Suvanasuthi S; Kulthanan K; Dhana N; Jongjarearnprasert K
    J Drugs Dermatol; 2012 Oct; 11(10):e43-7. PubMed ID: 23134998
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A cross-sectional study of cutaneous drug reactions in a private dental college and government medical college in eastern India.
    Chattopadhyay C; Chakrabarti N
    Niger J Clin Pract; 2012; 15(2):194-8. PubMed ID: 22718172
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A case of COVID-19 diagnosed with favipiravir-induced drug fever based on a positive drug-induced lymphocyte stimulation test.
    Murai Y; Kawasuji H; Takegoshi Y; Kaneda M; Kimoto K; Ueno A; Miyajima Y; Kawago K; Fukui Y; Ogami C; Sakamaki I; Tsuji Y; Morinaga Y; Yamamoto Y
    Int J Infect Dis; 2021 May; 106():33-35. PubMed ID: 33746092
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An adaptive randomised placebo controlled phase II trial of antivirals for COVID-19 infection (VIRCO): A structured summary of a study protocol for a randomised controlled trial.
    McMahon JH; Lau JSY; Roney J; Rogers BA; Trubiano J; Sasadeusz J; Molton JS; Gardiner B; Lee SJ; Hoy JF; Cheng A; Peleg AY
    Trials; 2020 Oct; 21(1):847. PubMed ID: 33050947
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial.
    Lou Y; Liu L; Yao H; Hu X; Su J; Xu K; Luo R; Yang X; He L; Lu X; Zhao Q; Liang T; Qiu Y
    Eur J Pharm Sci; 2021 Feb; 157():105631. PubMed ID: 33115675
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acute Gouty Arthritis During Favipiravir Treatment for Coronavirus Disease 2019.
    Hase R; Kurata R; Ishida K; Kurita T; Muranaka E; Mito H
    Intern Med; 2020 Sep; 59(18):2327-2329. PubMed ID: 32727996
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial.
    Li J; Zhang C; Wu Z; Wang G; Zhao H
    Trials; 2020 Jun; 21(1):488. PubMed ID: 32503657
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial.
    Udwadia ZF; Singh P; Barkate H; Patil S; Rangwala S; Pendse A; Kadam J; Wu W; Caracta CF; Tandon M
    Int J Infect Dis; 2021 Feb; 103():62-71. PubMed ID: 33212256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.